So, IMO management has two reasons for currently only talking about CF.
First, with the Orkambi price tag they want to emphasize to society as a whole that Vertex is a CF company devoted to addressing the unmet needs of CF patients, both those not currently served by the company and those who are and can benefit from even better drugs. Thus the North Carolina deal.
Second, the CEO is taking a more traditional Pharma approach to talking about his pipeline. Established companies who fund themselves with product revenues limit for competitive reasons their public discussion of what they have in their labs and clinics. No revenue biotechs need to excite investors who are the source of their funding and so talk earlier and more about their research. Mr. Leiden is playing it more close to the vest. Whether this is just smart or a way to manage his image time will tell. He certainly does make a good presentation, but then so did Carly Fiorina at HP before she screwed things up so royally.
What I get more interested in is Why the company hasn't said Anything about the two annual meeting resolutions that did not go management's way. May be this week will provide some answers but for now they just look like petulant, possibly passive aggressive children.
Finally, for those who are so concerned about Vertex being only a CF company I offer this thought: It is only possible to have a Second or Third or so on successful product when you have a sustainably successful First product and Vertex is rightly attending to that absolute precondition.